Cormorant Asset Management’s PTC Therapeutics PTCT Stock Holding History

Cormorant Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-8,500	Closed	-$517K	–	83
2015 Q1	$517K	Sell	8,500 -1,500	-15%	-$91.5K	0.08%	67
2014 Q4	$518K	Sell	10,000 -115,000	-92%	-$5.06M	0.08%	66
2014 Q3	$5.5M	Sell	125,000 -25,000	-17%	-$782K	1.13%	24
2014 Q2	$3.92M	Sell	150,000 -400,000	-73%	-$8.56M	1.04%	39
2014 Q1	$14.4M	Buy	550,000 +521,200	+1,810%	+$14M	3.31%	10
2013 Q4	$489K	Buy	+28,800	New	+$506K	0.14%	34

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Cormorant Asset Management's PTCT Position: Q2 2015 in Review

Cormorant Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 8,500 shares — an estimated $517K sold.

Cormorant Asset Management first reported a position in PTCT in Q4 2013 and held it in 6 quarters. The position peaked at $14.4M in Q1 2014. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

Cormorant Asset Management reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
Cormorant Asset Management sold 8,500 PTC Therapeutics shares in Q2 2015, an estimated $517K.
Cormorant Asset Management first reported a position in PTC Therapeutics in Q4 2013 and held it in 6 quarters.
Cormorant Asset Management's PTC Therapeutics position peaked at $14.4M in Q1 2014.
155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.